Key result
Intravenous administration of 30 nmol/kg (pyr1)-Apelin-13 significantly improved insulin sensitivity in healthy overweight men (ΔGIR 0.82 ± 0.71 mg/kg/min, P=0.033).
Why the study?
Does intravenous apelin administration improve insulin sensitivity in healthy overweight men?
RCT (n=16)
double-blind
randomized
Does intravenous apelin administration improve insulin sensitivity in healthy overweight men?
Mean Difference: 0.82
p-value: p=.033
Intravenous apelin administration improves insulin sensitivity in healthy overweight men, suggesting the apelin/APJ pathway as a potential therapeutic target for insulin resistance.
No takes yet. Share an insight, caveat, or question.
High-dose apelin improves insulin sensitivity in overweight men; first human RCT extends rodent findings and supports apelin/APJ pathway as therapeutic target.
Gourdy et al. (2017) conducted an RCT in Healthy overweight (n=16). (pyr1)-Apelin-13 vs. placebo was evaluated on difference in glucose infusion rate (GIR) between level 2 and level 1 (ΔGIR) (MD 0.82 mg/kg/min, p=.033). Intravenous administration of 30 nmol/kg (pyr1)-Apelin-13 significantly improved insulin sensitivity in healthy overweight men (ΔGIR 0.82 ± 0.71 mg/kg/min, P=0.033).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: